Cue Biopharma, Inc. (CUE) stock
CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
$14.10−2.02 (-12.53%)
Close on Nov 16, 2026Market cap $102.43MP/E –Yield –
Cue Biopharma total assets
Total assets on the balance sheet at the end of each period.
Cue Biopharma's total assets was $30.71M at Jun 30, 2026. For fiscal 2025 it was $42.21M, up 31.1% from the year before. The highest annual figure on record is $99.53M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.21M | +31.1% |
| FY2024 | Dec 31, 2024 | $32.19M | -47.7% |
| FY2023 | Dec 31, 2023 | $61.53M | -32.6% |
| FY2022 | Dec 31, 2022 | $91.28M | +9.5% |
| FY2021 | Dec 31, 2021 | $83.40M | -16.2% |
| FY2020 | Dec 31, 2020 | $99.53M | +39.0% |
| FY2019 | Dec 31, 2019 | $71.61M | +57.8% |
| FY2018 | Dec 31, 2018 | $45.36M | -32.2% |
| FY2017 | Dec 31, 2017 | $66.95M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $30.71M | -24.6% |
| Q1 FY2026 | Mar 31, 2026 | $30.88M | +38.7% |
| Q4 FY2025 | Dec 31, 2025 | $42.21M | +31.1% |
| Q3 FY2025 | Sep 30, 2025 | $31.64M | -29.4% |
| Q2 FY2025 | Jun 30, 2025 | $40.71M | -3.8% |
| Q1 FY2025 | Mar 31, 2025 | $22.25M | -58.8% |
| Q4 FY2024 | Dec 31, 2024 | $32.19M | -47.7% |
| Q3 FY2024 | Sep 30, 2024 | $44.81M | -35.0% |
| Q2 FY2024 | Jun 30, 2024 | $42.33M | -42.1% |
| Q1 FY2024 | Mar 31, 2024 | $53.95M | -33.9% |
| Q4 FY2023 | Dec 31, 2023 | $61.53M | -32.6% |
| Q3 FY2023 | Sep 30, 2023 | $68.89M | -9.7% |
| Q2 FY2023 | Jun 30, 2023 | $73.16M | -13.7% |
| Q1 FY2023 | Mar 31, 2023 | $81.68M | -9.9% |
| Q4 FY2022 | Dec 31, 2022 | $91.28M | +9.5% |
| Q3 FY2022 | Sep 30, 2022 | $76.30M | -3.3% |
| Q2 FY2022 | Jun 30, 2022 | $84.75M | -5.5% |
| Q1 FY2022 | Mar 31, 2022 | $90.70M | +2.2% |
| Q4 FY2021 | Dec 31, 2021 | $83.40M | -16.2% |
| Q3 FY2021 | Sep 30, 2021 | $78.88M | -26.0% |
| Q2 FY2021 | Jun 30, 2021 | $89.67M | -11.5% |
| Q1 FY2021 | Mar 31, 2021 | $88.72M | +46.3% |
| Q4 FY2020 | Dec 31, 2020 | $99.53M | +39.0% |
| Q3 FY2020 | Sep 30, 2020 | $106.62M | +135.8% |
| Q2 FY2020 | Jun 30, 2020 | $101.35M | +142.7% |
| Q1 FY2020 | Mar 31, 2020 | $60.65M | +34.2% |
| Q4 FY2019 | Dec 31, 2019 | $71.61M | +57.8% |
| Q3 FY2019 | Sep 30, 2019 | $45.21M | +1.4% |
| Q2 FY2019 | Jun 30, 2019 | $41.76M | -21.4% |
| Q1 FY2019 | Mar 31, 2019 | $45.19M | -23.8% |
| Q4 FY2018 | Dec 31, 2018 | $45.36M | -32.2% |
| Q3 FY2018 | Sep 30, 2018 | $44.58M | – |
| Q2 FY2018 | Jun 30, 2018 | $53.11M | – |
| Q1 FY2018 | Mar 31, 2018 | $59.33M | – |
| Q4 FY2017 | Dec 31, 2017 | $66.95M | – |
See a number that looks wrong?